Literature DB >> 7721959

Temporal variation of c-Fos proto-oncogene expression during osteoblast differentiation and osteogenesis in developing rat bone.

M Machwate1, A Jullienne, M Moukhtar, P J Marie.   

Abstract

To delineate the implication of c-fos protooncogenic in the osteogenie process, we have investigated the temporal pattern of c-fos mRNA expression in fetal and neonatal rat bone during intramembranous and endochondral bone formation. Northern blot analysis of mRNA extracted from calvaria and femur showed that expression of c-fos, Histone H4, and osteocalcin mRNAs followed a temporal sequence during bone development. The levels of histone H4 mRNA, a marker of cell proliferation, were high at early stages of fetal development of calvaria and femur, and decreased until birth. In both the postnatal calvaria and femur, c-fos mRNA levels increased transiently at birth and preceded a rise in osteocalcin transcripts, a marker of the mature osteoblast phenotype. The immunohistochemical analysis showed that c-Fos protein was expressed in osteoprogenitor cells in the perichondrium and periosteum, and not in mature osteoblasts which expressed markers of differentiated osteoblasts such as type-I collagen, bone sialoprotein, and osteocalcin. Thus, the transient c-fos proto-oncogene expression during the postnatal life that precedes the osteocalcin expression may be involved in the transition from the precursor state to mature osteoblasts. These results suggest that c-fos proto-oncogene may play an important role in osteogenesis during rat postnatal life.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721959     DOI: 10.1002/jcb.240570108

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to Gsalpha mutation at the Arg201 codon: polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-embedded tissues.

Authors:  A Sakamoto; Y Oda; Y Iwamoto; M Tsuneyoshi
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

2.  Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

Authors:  Sumana Posritong; Jung Min Hong; Pierre P Eleniste; Patrick W McIntyre; Jennifer L Wu; Evan R Himes; Vruti Patel; Melissa A Kacena; Angela Bruzzaniti
Journal:  Mol Cell Endocrinol       Date:  2018-02-08       Impact factor: 4.102

3.  Osteoblasts responses to three-dimensional nanofibrous gelatin scaffolds.

Authors:  Ashneet Sachar; T Amanda Strom; Maria J Serrano; M Douglas Benson; Lynne A Opperman; Kathy K H Svoboda; Xiaohua Liu
Journal:  J Biomed Mater Res A       Date:  2012-06-15       Impact factor: 4.396

4.  Increased proliferation of osteoblastic cells expressing the activating Gs alpha mutation in monostotic and polyostotic fibrous dysplasia.

Authors:  P J Marie; C de Pollak; P Chanson; A Lomri
Journal:  Am J Pathol       Date:  1997-03       Impact factor: 4.307

5.  Role of diabetes- and obesity-related protein in the regulation of osteoblast differentiation.

Authors:  Gabriel R Linares; Weirong Xing; Hans Burghardt; Bernhard Baumgartner; Shin-Tai Chen; Wifredo Ricart; José Manuel Fernández-Real; Antonio Zorzano; Subburaman Mohan
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-05       Impact factor: 4.310

6.  Effects of verapamil on the immediate-early gene expression of bone marrow mesenchymal stem cells stimulated by mechanical strain in vitro.

Authors:  Runguang Li; Mingfa Wei; Jingfan Shao
Journal:  Med Sci Monit Basic Res       Date:  2013-02-21

7.  Clinical trial and in-vitro study comparing the efficacy of treating bony lesions with allografts versus synthetic or highly-processed xenogeneic bone grafts.

Authors:  Eva Johanna Kubosch; Anke Bernstein; Laura Wolf; Tobias Fretwurst; Katja Nelson; Hagen Schmal
Journal:  BMC Musculoskelet Disord       Date:  2016-02-13       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.